Cigna (NYSE:CI) stock closed 2.1% lower on January 3 after the Wall Street Journal reported that the company is exploring the sale of its Medicare business. This marks a shift in the healthcare and insurance company’s strategy, which had previously focused on expanding in the fast-growing medical sector.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Per the report, Cigna is in advanced talks with the Health Care Service Corporation. Moreover, the estimated valuation for the proposed transaction ranges between $3 billion and $4 billion. However, given the investors’ initial reaction to the announcement, this valuation seems relatively modest. It’s worth noting that Cigna’s Medicare business, recognized as Medicare Advantage, achieved revenues of $6.6 billion in the first nine months of 2023, indicating a year-over-year growth of approximately 9%.
The move follows Cigna’s failed merger deal with Humana (NYSE:HUM). Last month, Cigna dropped its merger plan following resistance from shareholders. The company then said it would focus on growing its presence in the health insurance sector via bolt-on acquisitions. Additionally, the company plans to allocate a significant portion of its cash for share buybacks in 2024 and has approved a new share repurchase plan worth $10 billion.
With this background, let’s look at the Street’s recommendation for Cigna.
Is Cigna a Good Stock to Buy Now?
Wall Street analysts are cautiously optimistic about Cigna stock. With seven Buy and seven Hold recommendations, Cigna has a Moderate Buy consensus rating. Meanwhile, analysts’ average price target of $365.33 implies 20.31% upside potential from current levels.
